Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264731 | 0.88 | LMNA (0.41) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL943184 | 0.88 | TYMP (0.43) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL12427963 | 0.88 | TYMP (0.43) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL12427881 | 0.88 | TYMP (0.43) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL12427908 | 0.85 | TYMP (0.44) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL27829237 | 0.83 | DRD2 (0.42) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL941683 | 0.82 | LMNA (0.61) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL12427903 | 0.82 | TYMP (0.46) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL12427919 | 0.81 | TYMP (0.42) | LMNATHRBCYP2C19TYMPCA12 | |
| SCHEMBL12264736 | 0.81 | DGAT1 (0.38) | LMNATHRBCYP2C19TYMPCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| CN-101652360-B | Nitroimidazol hypoxic contrast agents | SIEMENS MEDICAL SOLUTIONS US | 2014-06-25 | — | — | CN | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| CN-101652360-A | Nitroimidazol hypoxic contrast agents | SIEMENS MEDICAL SOLUTIONS US | 2010-02-17 | — | — | CN | disclosed |
| EP-2132200-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | Siemens Medical Solutions USA, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008124651-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | LMNA 3765/4885THRB 2300/4885CYP2C19 277/4885 |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | LMNA 3725/4885THRB 2243/4885CYP2C19 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.